vs
Side-by-side financial comparison of Invesco (IVZ) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Invesco is the larger business by last-quarter revenue ($1.7B vs $1.1B, roughly 1.5× PERRIGO Co plc). Invesco runs the higher net margin — -58.9% vs -127.8%, a 68.9% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs -2.5%). Invesco produced more free cash flow last quarter ($432.2M vs $148.6M). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs 1.3%).
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
IVZ vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $1.1B |
| Net Profit | $-995.9M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | -86.2% | -116.0% |
| Net Margin | -58.9% | -127.8% |
| Revenue YoY | 6.2% | -2.5% |
| Net Profit YoY | -575.8% | -3093.9% |
| EPS (diluted) | $-2.61 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.5B | $1.0B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.5B | $1.1B |
| Q4 25 | $-995.9M | $-1.4B | ||
| Q3 25 | $356.4M | $7.5M | ||
| Q2 25 | $197.4M | $-8.4M | ||
| Q1 25 | $171.1M | $-6.4M | ||
| Q4 24 | $209.3M | $-44.4M | ||
| Q3 24 | $55.0M | $-21.0M | ||
| Q2 24 | $132.2M | $-108.4M | ||
| Q1 24 | $141.5M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | -86.2% | -116.0% | ||
| Q3 25 | 16.5% | 7.0% | ||
| Q2 25 | 14.1% | 4.3% | ||
| Q1 25 | 18.1% | 4.5% | ||
| Q4 24 | 19.6% | 10.0% | ||
| Q3 24 | 6.6% | 7.4% | ||
| Q2 24 | 13.9% | -2.5% | ||
| Q1 24 | 14.4% | -5.1% |
| Q4 25 | -58.9% | -127.8% | ||
| Q3 25 | 21.7% | 0.7% | ||
| Q2 25 | 13.0% | -0.8% | ||
| Q1 25 | 11.2% | -0.6% | ||
| Q4 24 | 13.1% | -3.9% | ||
| Q3 24 | 3.6% | -1.9% | ||
| Q2 24 | 8.9% | -10.2% | ||
| Q1 24 | 9.6% | 0.2% |
| Q4 25 | $-2.61 | $-10.23 | ||
| Q3 25 | $0.66 | $0.05 | ||
| Q2 25 | $-0.03 | $-0.06 | ||
| Q1 25 | $0.38 | $-0.05 | ||
| Q4 24 | $0.46 | $-0.32 | ||
| Q3 24 | $0.12 | $-0.15 | ||
| Q2 24 | $0.29 | $-0.79 | ||
| Q1 24 | $0.31 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0B | — |
| Total DebtLower is stronger | $1.8B | — |
| Stockholders' EquityBook value | $12.2B | $2.9B |
| Total Assets | $27.1B | $8.5B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $973.1M | $432.1M | ||
| Q2 25 | $922.7M | $454.2M | ||
| Q1 25 | $821.7M | $409.9M | ||
| Q4 24 | $986.5M | $558.8M | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $878.5M | $542.8M | ||
| Q1 24 | $895.7M | $658.5M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $964.8M | — | ||
| Q4 24 | $890.6M | — | ||
| Q3 24 | $890.3M | — | ||
| Q2 24 | $890.1M | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | $12.2B | $2.9B | ||
| Q3 25 | $14.0B | $4.4B | ||
| Q2 25 | $13.9B | $4.5B | ||
| Q1 25 | $14.7B | $4.4B | ||
| Q4 24 | $14.6B | $4.3B | ||
| Q3 24 | $14.8B | $4.6B | ||
| Q2 24 | $14.6B | $4.5B | ||
| Q1 24 | $14.6B | $4.7B |
| Q4 25 | $27.1B | $8.5B | ||
| Q3 25 | $28.4B | $10.1B | ||
| Q2 25 | $28.5B | $10.1B | ||
| Q1 25 | $28.1B | $9.8B | ||
| Q4 24 | $27.0B | $9.6B | ||
| Q3 24 | $27.5B | $11.2B | ||
| Q2 24 | $27.2B | $10.4B | ||
| Q1 24 | $28.1B | $10.6B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | 0.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $455.8M | $175.4M |
| Free Cash FlowOCF − Capex | $432.2M | $148.6M |
| FCF MarginFCF / Revenue | 25.5% | 13.4% |
| Capex IntensityCapex / Revenue | 1.4% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.4B | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $455.8M | $175.4M | ||
| Q3 25 | $606.2M | $51.7M | ||
| Q2 25 | $547.9M | $75.9M | ||
| Q1 25 | $-84.6M | $-64.5M | ||
| Q4 24 | $316.9M | $312.6M | ||
| Q3 24 | $438.4M | $42.2M | ||
| Q2 24 | $489.1M | $9.5M | ||
| Q1 24 | $-54.4M | $-1.4M |
| Q4 25 | $432.2M | $148.6M | ||
| Q3 25 | $586.4M | $29.8M | ||
| Q2 25 | $530.4M | $56.7M | ||
| Q1 25 | $-108.0M | $-90.0M | ||
| Q4 24 | $309.9M | $274.9M | ||
| Q3 24 | $410.0M | $15.1M | ||
| Q2 24 | $462.4M | $-18.9M | ||
| Q1 24 | $-75.4M | $-26.5M |
| Q4 25 | 25.5% | 13.4% | ||
| Q3 25 | 35.7% | 2.9% | ||
| Q2 25 | 35.0% | 5.4% | ||
| Q1 25 | -7.1% | -8.6% | ||
| Q4 24 | 19.5% | 24.2% | ||
| Q3 24 | 27.1% | 1.4% | ||
| Q2 24 | 31.2% | -1.8% | ||
| Q1 24 | -5.1% | -2.4% |
| Q4 25 | 1.4% | 2.4% | ||
| Q3 25 | 1.2% | 2.1% | ||
| Q2 25 | 1.2% | 1.8% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 0.4% | 3.3% | ||
| Q3 24 | 1.9% | 2.5% | ||
| Q2 24 | 1.8% | 2.7% | ||
| Q1 24 | 1.4% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | 1.70× | 6.89× | ||
| Q2 25 | 2.78× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 1.51× | — | ||
| Q3 24 | 7.97× | — | ||
| Q2 24 | 3.70× | — | ||
| Q1 24 | -0.38× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IVZ
| Investment Advice | $1.2B | 73% |
| Distribution And Shareholder Service | $382.7M | 23% |
| Financial Service Other | $51.0M | 3% |
| Investment Performance | $28.9M | 2% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
